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Abstract
Background: A recent trial involving predominantly Caucasian subjects with Parkinson Disease (PD) showed
switching overnight from an oral dopaminergic agonist to the rotigotine patch was well tolerated without loss of
efficacy. However, no such data have been generated for Korean patients.
Methods: This open-label multicenter trial investigated PD patients whose symptoms were not satisfactorily
controlled by ropinirole, at a total daily dose of 3 mg to 12 mg, taken as monotherapy or as an adjunct to
levodopa. Switching treatment from oral ropinirole to transdermal rotigotine was carried out overnight, with a
dosage ratio of 1.5:1. After a 28-day treatment period, the safety and tolerability of switching was evaluated. Due to
the exploratory nature of this trial, the effects of rotigotine on motor and nonmotor symptoms of PD were
analyzed in a descriptive manner.
Results: Of the 116 subjects who received at least one treatment, 99 (85%) completed the 28-day trial period.
Dose adjustments were required for 11 subjects who completed the treatment period. A total of 76 treatment-
emergent adverse events (AEs) occurred in 45 subjects. No subject experienced a serious AE. Thirteen subjects
discontinued rotigotine prematurely due to AEs. Efficacy results suggested improvements in both motor and
nonmotor symptoms and quality of life after switching. Fifty-two subjects (46%) agreed that they preferred using
the patch over oral medications, while 31 (28%) disagreed.
Conclusions: Switching treatment overnight from oral ropinirole to transdermal rotigotine patch, using a dosage
ratio of 1.5:1, was well tolerated in Korean patients with no loss of efficacy.
Trial registration: This trial is registered with the ClincalTrails.gov Registry (NCT00593606).
Background
Long term use of levodopa, the standard treatment for
Parkinson’s disease (PD), is associated with the develop-
ment of motor complications, including motor fluctua-
tions and dyskinesias [1]. Considerable evidence suggests
that these motor symptoms are related to nonphysiologi-
cal, pulsatile stimulation of dopamine receptors due to
the intermittent administration of levodopa [2]. The
longer half lives of dopamine agonists suggest they may
provide more continuous and less pulsatile dopaminergic
stimulation [3-5]. Their use can delay the initiation of
levodopa treatment, a factor contributing to their
widespread clinical acceptance. However, most currently
available dopamine agonists require administration via
multiple oral doses throughout the day, potentially lead-
ing to lower compliance and, albeit to a lesser degree
than levodopa, motor fluctuations.
Rotigotine is a nonergolinic selective D3/D2/D1 dopami-
nergic agonist formulated in a silicone-based transdermal
patch for once-daily application. It is released continuously
over a 24-hour period and may provide more stable
plasma concentrations than orally administered drugs.
Studies have demonstrated safety and efficacy of the roti-
gotine patch, both in patients with early and advanced PD
[6-8]. A recent trial involving predominantly Caucasian
subjects showed switching PD treatment overnight from
an oral dopaminergic agonist to the rotigotine patch can
be well tolerated without loss of efficacy in terms of the
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[9]. Overnight switching offers advantages over slow con-
version, as a slow down-titration of the current medication
and a slow up-titration of another are time-consuming,
and can be associated with worsening of PD. However, no
such data for rotigotine have been generated for Korean
patients.
In this trial, the safety and tolerability of an overnight
switch from ropinirole to the rotigotine transdermal
patch, and the effects on motor and nonmotor symp-
toms of PD in Korean patients were investigated.
Methods
Patients
This open-label, multicenter trial was conducted at 8
sites in Korea between July and December 2007. Eligible
subjects were Korean, male or female, aged 18 years or
older with a diagnosis of PD (Hoehn and Yahr Stage
I-IV) not satisfactorily controlled by ropinirole at a total
daily dose of 3-12 mg, taken either as monotherapy or as
an adjunct to levodopa. If subjects were receiving addi-
tional PD medications, including levodopa, anticholiner-
gics, selegiline, amantadine, or entacapone, the total daily
doses were maintained at a stable dose for at least 28
days before the study baseline and for the duration of the
trial. Subjects were excluded if they had atypical parkin-
sonism; dementia, active psychosis, or hallucinations;
clinically significant cardiac, renal or hepatic diseases;
significant skin hypersensitivity to adhesive or other
transdermal medications; recent contact dermatitis;
symptomatic orthostatic hypotension; corrected QT
interval of 500 ms or greater on electrocardiogram at
pre-treatment evaluation or baseline or were pregnant or
nursing. Prohibited medications included recent use of
a-methyldopa, metoclopramide, neuroleptics, monoa-
mine oxidase A inhibitors, methylphenidate, or ampheta-
mine. Patients with evidence of an impulse control
disorder (ICD) according to the Modified Minnesota
Impulsive Disorder Interview (mMIDI) [10] at pre-treat-
ment evaluation were also excluded.
Study design
This trial was conducted in accordance with the
Declaration of Helsinki and Good Clinical Practice
Guidelines. The trial protocol was approved by the insti-
tutional review board at each center involved. All sub-
jects provided informed consent prior to enrolment and
could withdraw at any time.
Treatments
Baseline data (Day 0) were recorded following an up to
28-day pre-treatment observation period, during which
patient eligibility was confirmed and ropinirole and all
other PD medications were maintained at stable doses.
Subjects were planned to take their final dose of ropinir-
ole in the afternoon or evening, and to apply a rotigo-
tine patch upon awakening the next morning (Day 1).
Switching from oral ropinirole to rotigotine patch was
proposed to be done according to a predetermined
dosage scheme: 3 mg/day ropinirole to 2 mg/24 hr roti-
gotine, 6 mg/day to 4 mg/24 hr, 8 or 9 mg/day to 6 mg/
24 hr, and 12 mg/day to 8 mg/24 hr [9,11]. Throughout
the 28-day treatment period patches were to be worn
continuously for 24 hours prior to removal, at which
point a new patch was to be immediately applied at a
different position on the skin. Rotigotine dose adjust-
ment by 2 mg/24 hr per week was allowed to optimize
dosing. Following the treatment period, subjects entered
the de-escalation period for up to 6 days, followed by a
28-day safety follow-up period.
Evaluations
Efficacy of rotigotine was assessed by change from base-
line to the end of treatment (EOT) using the Unified
Parkinson’s Disease Rating Scale (UPDRS) parts I, II, III,
and IV. Changes in sleep-related problems were mea-
sured by the modified Parkinson’s Disease Sleep Scale
(mPDSS) [12] and the Epworth Sleepiness Scale (ESS).
Changes in nonmotor symptoms were measured by the
Non-motor Symptom Assessment Scale (NMSS) [13].
The severity of illness and global improvements were
determined by the Clinical Global Impression (CGI),
Patient Global Impression (PGI), and Parkinson’sD i s -
ease Questionnaire (PDQ-8), in addition to a patient
treatment preference scale. The efficacy scale assessment
w a sd o n eb yt h ep a t i e n t ’s neurologist. A Full Analysis
Set, including all subjects with at least one valid post-
baseline efficacy assessment, was used for efficacy eva-
luations. Due to the exploratory nature of this trial, only
descriptive analyses were performed.
Blood sampling to determine unconjugated and total
rotigotine plasma concentration (total rotigotine as the
sum of the parent compound and its conjugates) was
done prior to patch removal at the EOT visit (Day 28).
Samples were analyzed using a liquid chromatography-
mass spectrometry or mass spectrometry method. Roti-
gotine is metabolized to a great extent. Rotigotine is
metobolised by N-dealkylation as well as direct and sec-
ondary conjugation. The main metabolites are sulfates
and glucuronide conjugates of the parent compound
and of the N-desalkyl-metabolites, which are biologically
inactive.
Safety measures at baseline and at EOT included analy-
sis of adverse events (AEs) and clinical laboratory evalua-
tions, physical and neurological examinations,
monitoring of changes in vital signs, body weight, and
electrocardiograms, assessment of patch application sites,
and results of the mMIDI. Treatment-emergent AEs
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date of first dose of rotigotine, or pre-existing events
whose severity worsened on or after that date. In applica-
tion site assessment, all abnormal clinically significant
observations, other than reddening limited to the patch
area after removal of the patch, was recorded as AEs. All
subjects who applied at least one rotigotine patch were
included in the analysis of safety (safety set).
Tolerability of switching was assessed by the following:
(1) total number of subjects completing the trial, with or
without adjustments to their original rotigotine dose
assignment, (2) total number of subjects who discontin-
ued or had dose reductions during the 5 half-life overlap
period (the time from day of first treatment with rotigo-
tine through 5 half lives of ropinirole), (3) total number
of subjects who discontinued or had dose reductions due
to AEs with onset during the 5 half-life overlap period
and (4) incidence rates of AEs prior to, during, and after
the switch (5 half-life overlap period) to rotigotine
Results
Subjects and Treatment Regimens
Of the 124 subjects enrolled, 116 (94%) received at least
one dose of rotigotine and 99/116 (85%) completed the
28-day treatment period. The clinical and demographic
characteristics of the subjects are listed in Table 1. The
doses of rotigotine initiated at baseline were 2 mg/24 hr
in 26 subjects, 4 mg/24 hr in 30 subjects, 6 mg/24 hr in
31 subjects, and 8 mg/24 hr in 29 subjects.
Efficacy
Rotigotine treatment resulted in small mean decreases in
UPDRS I, II, III, and IV (Table 2). Compared with base-
line, mean UPDRS III score was reduced from 17.9 ±
10.3 (n = 114) to 15.9 ± 10.0 (n = 112).
Measurements of sleep-related symptoms showed no
substantial changes. The mean mPDSS score was 12.7 at
baseline (n = 114), and the change from baseline to EOT
was -0.8 (n = 112). The mean ESS score was 6.0 at baseline
(n = 63) and 5.7 at EOT (n = 57). At baseline six subjects
were defined as excessively sleepy (ESS ≥10), of whom five
no longer experienced excessive somnolence at EOT.
Three additional subjects, who were not considered exces-
sively sleepy at baseline, were classified as excessively
sleepy following treatment with rotigotine.
A reduction of 7.9 in the total NMSS score was observed
at EOT (n = 111, Table 2). The baseline total NMSS score
was 29.5 ± 30.5 (n = 114). Scores for each of the individual
domains showed a reduction from baseline.
At EOT, CGI scores as assessed by investigators indi-
cated that 54 subjects were considered improved, while
22 were considered worsened and 37 had no change (n
= 114). In the remaining one patient, CGI score was
not assessed. The mean CGI score for global improve-
ment was 3.6, indicating an average assessment of mini-
mally improved to no change. The PGI scores showed
that 54 subjects reported improvement, while 27 sub-
jects reported worsening (n = 114). As part of this rat-
ing, 77 subjects reported having no side effects, and 24
subjects reported side effects that ‘did not significantly
interfere’ with their functioning. In five cases patients
considered their side effects ‘outweighed the therapeutic
effect.’
The mean baseline PDQ-8 score was 22.3 (n = 114), and
the change from baseline to EOT was -3.9 (n = 112), indi-
cating some improvement in the occurrence of various
problems associated with PD upon switching to rotigotine.
Patient treatment preference scale analysis at EOT
showed that slightly less than half of the subjects (52 of
114 subjects, 46%) agreed that they preferred using a
patch over oral medications, while 31 (28%) disagreed and
29 (26%) neither agreed nor disagreed. The proportions of
subjects who were either ‘satisfied’ or ‘very satisfied’ were
37% with rotigotine and 44% with ropinirole. The aspects
of the patch that subjects liked the most were once-a-day
application (72%), non-interference with normal activities
(54%), and not having to remember to take medicine dur-
ing the day (54%). The aspect that subjects liked the least
was the patch not staying on for the entire day (71%). As
determined by the investigator at EOT, patch adhesiveness
for the last patch administered was < 50% in three of 73
subjects assessed; in two of these subjects the patch was
“detached”.
Safety and Tolerability
Of the 99 subjects who switched from ropinirole and
completed the treatment period, most (n = 88) did not
require rotigotine dose adjustment. Of the 11 who did
require dose adjustment 10 required a dose increase,
Table 1 Baseline Characteristics (safety set)
N = 116
Age, yrs ± SD 60.0 ± 10.1
Gender, male, n (%) 69 (59.5)
Body weight, kg ± SD 64.2 ± 9.5
BMI, kg/m
2 ± SD 24.2 ± 2.9
Duration of PD, yrs ± SD 5.4 ± 4.0
H&Y stage, n (%)
1 21 (18.1)
2 69 (59.5)
3 21 (18.1)
4 5 (4.3)
Concomitant PD medication, n (%)
Levodopa 100 (86.2)
Amantadine 61 (52.6)
Selegiline 61 (52.6)
SD = Standard Deviation.
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initial dose.
A total of 76 treatment-emergent AEs were reported in
45 subjects (39%), none of which were considered ser-
ious. The most commonly reported AEs were dizziness
and tremor (Table 3). AEs were generally mild or moder-
ate in intensity, with a severe AE reported by only one
subject, who experienced a severe dyskinesia after 15
days of treatment. The dyskinesia resolved the next day
without a change in rotigotine dose. The incidence rate
of AEs was highest during the overlap period (0.112 AEs
per day) compared with prior to (0.004) or after the 5
half-life overlap period (0.008). Sixteen subjects
experienced a total of 26 AEs that started during the
overlap period, of which the most common were somno-
lence, dizziness, dyskinesia, and tremor, reported by
three subjects each. No subject developed impulse con-
trol disorder during the trial.
The total number of subjects who discontinued due to
AEs with onset during the 5 half-life overlap period was
9(7.8%) and the total number of subjects who had dose
reductions due to AEs with onset during the 5 half-life
overlap period was 1(0.9%). The total number of sub-
jects who discontinued during the 5 half-life overlap
period (the time from day of first treatment with rotigo-
tine through 5 half lives of ropinirole) was 0(0%) and
the total number of subjects who had dose reductions
during the 5 half life overlap period (the time from day
of first treatment with rotigotine through 5 half lives of
ropinirole) was 1(0.9%). AEs that led to discontinuation
of more than one subject were tremor and dizziness
(three each), and aggravated parkinsonism and dyskine-
sia (two each). However, no AE that led to discontinua-
tion was severe in intensity and all were resolved by
EOT.
In skin assessment, eleven subjects experienced mini-
mal and barely perceptible erythema and three experi-
enced definite erythema with minimal edema limited to
the patch area at application sites. Itching at the applica-
tion site developed in 17 subjects and was considered
clinically relevant in three subjects. Because only clini-
cally significant observations were counted as AEs in
skin assessment (see Methods), only these three subjects
were listed in Table 3. One of these three subjects
Table 2 UPDRS scores and NMSS scores at baseline and end of treatment
Baseline (n = 114) End of Treatment (n = 112) Difference (n = 112)
UPDRS
I 1.9 ± 1.8 1.4 ± 1.6 -0.5 ± 1.2
II 7.8 ± 5.3 6.9 ± 4.9 -0.9 ± 3.3
III 17.9 ± 10.3 15.9 ± 10.0 -1.9 ± 5.9
IV 2.7 ± 3.1 2.2 ± 2.8 -0.4 ± 1.8
Baseline (n = 114) End of Treatment (n = 111) Difference (n = 111)
NMSS
Total 29.5 ± 30.5 21.8 ± 22.2 -7.9 ± 19.8
Cardiovascular 0.8 ± 1.3 0.7 ± 2.6 -0.0 ± 2.7
Sleep/fatigue 5.8 ± 7.3 4.8 ± 6.0 -0.9 ± 6.7
Mood/cognition 4.6 ± 9.1 2.7 ± 6.6 -1.9 ± 6.2
Perceptual problems 0.2 ± 1.3 0.1 ± 0.7 -0.1 ± 1.1
Attention/memory 3.4 ± 4.7 2.4 ± 4.1 -1.0 ± 3.7
Gastrointestinal 2.3 ± 4.0 1.7 ± 3.0 -0.6 ± 3.6
Urinary 6.3 ± 9.9 5.2 ± 7.6 -1.3 ± 5.3
Sexual dysfunction 1.3 ± 3.5 0.9 ± 3.2 -0.4 ± 1.8
Miscellaneous 4.8 ± 6.4 3.3 ± 5.4 -1.6 ± 5.6
UPDRS, Unified Parkinson’s Disease Rating Scale; NMSS, Non-Motor Symptom Scale.
Plus-minus values are mean ± SD (Standard Deviation).
Table 3 The most common treatment-emergent adverse
events with an incidence of 2% or greater
Treatment-emergent adverse event Incidence, n
(%)
Dizziness 7 (6.0)
Tremor 7 (6.0)
Dyskinesia 6 (5.2)
Bradykinesia 4 (3.4)
Somnolence 4 (3.4)
Muscle Rigidity 5 (4.3)
Asthenia 6 (5.2)
Dry mouth 4 (3.4)
Application and Instillation Site Reactions*/Application
site pruritis
3 (2.6)
*Application and Instillation Site Reactions(MedDRA high-level term, MedDRA
version 9.1) comprising erythema, pruritus, rash, irritation, eczema, vesicles,
inflammation, and other reactions. Application site pruritus was the only
Preferred Term for this High Level Term.
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the application site.
Pharmacokinetics
Mean unconjugated and total rotigotine plasma concen-
trations under steady-state conditions in subjects
increased in a dose-proportional manner (Table 4). The
ratio of total rotigotine to unconjugated rotigotine was
similar at all doses evaluated.
Discussion
This open-label trial showed that switching dopaminergic
PD treatment overnight from oral ropinirole to transder-
mal rotigotine patch was generally well tolerated without
loss of efficacy. Most AEs were consistent with stimula-
tion of dopaminergic receptors or the use of a transder-
mal patch, with an incidence that was lower than or
comparable to previous studies with rotigotine patch
[7,9]. This trial was not designed to make determinations
regarding the efficacy of rotigotine and not powered to
show superiority of one drug over the other. However,
substituting rotigotine for ropinirole appeared to improve
both motor and nonmotor symptoms of PD, as measured
by reductions from baseline values in UPDRS, NMSS,
mPDSS, and ESS scores. A randomized controlled trial
has demonstrated significant benefits with rotigotine ver-
sus placebo in the control of motor function and noctur-
nal sleep disturbance in PD patients [14].
It should be noted that the observed improvements
occurred with a dosage conversion rate of 1.5:1 for ropi-
nirole to rotigotine. In a previous overnight switch study,
higher doses of rotigotine were used, in a dosage conver-
sion rate of 1:1, but the reduction in UPDRS III score
after switch from ropinirole to rotigotine was smaller
than in the current study [9]. The seemingly greater
potency of rotigotine in this trial is not likely to be due to
the differences in pharmacokinetics, as the plasma con-
centration of rotigotine was comparable to plasma con-
centrations obtained in other studies [15,16]. However, it
may be attributable to differences in ethnicity, as pre-
vious studies enrolled predominantly Caucasian subjects,
or the baseline severity of PD motor symptoms.
It is not clear whether the reductions in scores for
nonmotor symptoms are related to the reduction in
scores for severity of motor symptoms. Some studies
have shown a correlation between motor and nonmotor
symptoms [13,17,18]. However, the absence of a correla-
tion has also been reported [19,20], and it is possible
that the reduction in scores for nonmotor symptoms
after switching reflects a difference between ropinirole
and rotigotine’s effects on nonmotor symptoms, inde-
pendent of motor symptoms [21].
Conclusions
This trial showed that overnight switch from oral ropi-
nirole to transdermal rotigotine, with a dose conversion
ratio of 1.5:1, was well tolerated in Korean patients with
no apparent loss of efficacy. However, due to the open-
label design and exploratory nature of this trial, further
investigation will be required to ascertain the relative
efficacy of the rotigotine patch following a switch from
oral ropinirole.
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Table 4 Rotigotine plasma concentrations at end of treatment
Daily
rotigotine dose
n≧LOQ ng/mL
(unconjugated)
ng/mL
(total)
Ratio (total rotigotine/
unconjugated rotigotine)
2 mg/24 hr 14 0.265 ± 0.146 1.995 ± 0.736 8.447 ± 2.919
4 mg/24 hr 24 0.559 ± 0.236 4.157 ± 1.534 7.922 ± 2.753
6 mg/24 hr 27 0.928 ± 1.005 6.620 ± 3.962 8.802 ± 4.871
8 mg/24 hr 23 1.215 ± 0.790 7.433 ± 4.423 6.968 ± 3.071
Plus-minus values are mean ± SD (Standard Deviation).
LOQ = limit of quantification (0.01 ng/mL for unconjugated Rotigotine, 0.01 ng/mL for total Rotigotine)
Note: Values below LOQ were replaced by 0 in calculations (Mean, SD, CV, Med, Min, Max)
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